ADVENT CAPITAL MANAGEMENT /DE/ - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 51 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
ADVENT CAPITAL MANAGEMENT /DE/ ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2021$4,000
-100.0%
4,000
-100.0%
0.00%
-100.0%
Q1 2021$22,755,000
+4.8%
27,701,000
+1.1%
0.49%
+5.8%
Q4 2020$21,720,000
-7.5%
27,397,000
-5.5%
0.46%
-10.6%
Q3 2020$23,479,000
+9.2%
28,978,000
-0.2%
0.52%
+2.8%
Q2 2020$21,495,000
-27.0%
29,044,000
-19.6%
0.50%
-21.2%
Q1 2020$29,433,000
-35.0%
36,111,000
-19.1%
0.64%
-27.0%
Q4 2019$45,282,000
+15.2%
44,625,000
-2.4%
0.88%
+19.0%
Q3 2019$39,322,000
-14.0%
45,740,000
-10.7%
0.74%
-16.7%
Q2 2019$45,744,000
-10.8%
51,245,000
-1.0%
0.88%
-21.8%
Q1 2019$51,281,000
+140.3%
51,747,000
+123.8%
1.13%
+119.2%
Q4 2018$21,341,000
-26.8%
23,118,000
-19.9%
0.52%
-14.1%
Q3 2018$29,171,000
+32.9%
28,863,000
+15.0%
0.60%
+30.1%
Q2 2018$21,948,000
+27.4%
25,100,000
+16.7%
0.46%
+36.7%
Q1 2018$17,230,000
-11.8%
21,513,000
-11.9%
0.34%
-9.6%
Q4 2017$19,539,000
+1.1%
24,415,000
-1.4%
0.37%
+2.2%
Q3 2017$19,323,000
+158.8%
24,766,000
+222.1%
0.37%
+155.9%
Q2 2017$7,467,000
+2.3%
7,688,000
-1.7%
0.14%
+4.4%
Q1 2017$7,302,000
-12.3%
7,823,000
-15.7%
0.14%
-10.5%
Q4 2016$8,330,000
-19.8%
9,279,000
-0.0%
0.15%
+2.0%
Q3 2016$10,387,000
+0.8%
9,281,000
-7.2%
0.15%
-5.7%
Q2 2016$10,301,00010,000,0000.16%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2019
NameSharesValueWeighting ↓
SILVERBACK ASSET MANAGEMENT LLC 12,851,000$12,016,0002.95%
Context Capital Management, LLC 3,000,000$2,804,0002.24%
Man Investments (CH) AG 3,000,000$2,798,0001.76%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 42,500,000$39,540,0001.52%
MACKAY SHIELDS LLC 17,069,000$15,982,0000.73%
HIGHFIELDS CAPITAL MANAGEMENT LP 73,035,000$68,425,0000.63%
WOLVERINE ASSET MANAGEMENT LLC 42,307,000$39,554,0000.61%
LINDEN ADVISORS LP 14,122,000$13,194,0000.49%
GLG LLC 9,100,000$8,486,0000.47%
Jabre Capital Partners S.A. 3,400,000$3,179,0000.38%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders